Guidelines Panel Meeting: Early Detection of Prostate Cancer (2022)

September 1, 2022 to September 14, 2022

Panel members will be reviewing evidence prepared and presented by a methodologist who has been extracting and analyzing data from research articles. The panelists will inquire about aspects of the evidence and the methodologist will provide explanations. The panel will discuss the evidence and deliberate on the best practice methods to detect early stages of prostate cancer.

Target Audience

This activity is limited to Early Detection of Prostate Cancer Guidelines Panel Members only. 

Learning Objectives

After completing this activity, participants will be able to:

  1. Analyze the latest scientific evidence for early detection of prostate cancer.
  2. Recommend appropriate screening methods for detecting prostate cancer at an early stage.
  3. Apply improved critical thinking skills to medical literature reviews.
Course summary
Available credit: 
  • 11.00 AMA PRA Category 1 Credit™
  • 11.00 Non-Physician Participation
Course opens: 
Course expires: 
Event starts: 
09/01/2022 - 6:00pm EDT
Event ends: 
09/14/2022 - 11:00pm EDT


Thursday, September 1, 2022

6:00-6:10pm       Welcome and Introductions                                                                     Sennett Kim

6:10-6:20pm       Conflict of Interest Disclosures and Panel Responsibilities               Sennett Kim

6:20-8:45pm       EDPC Evidence Overview                                                                          Lesley Souter

8:45-9:00pm       Questions/Comments


Monday, September 12, 2022

6:00-6:15pm       Introduction to review of Statement Development                           Dr. Wei, MD

6:15-8:45pm       Guideline Statement Development                                                       Panel

8:45-9:00pm       Questions/Comments


Wednesday, September 14, 2022

6:00-8:45pm       Continue Guideline Statement Development                                      Panel

8:45-9:00pm       Questions/Comments and Next Steps

Thursday, September 29, 2022

6:00-7:45pm       Continue working on remaining statements                                        Panel

7:45-8:00pm       Working groups to provide updates on writing                                  Panel

and address questions for the chairs

*All Eastern Time

The Early Detection of Prostate Cancer Guidelines Panel have the following disclosures. 

NameCompany NameRoleFinancialEnd Date
Barocas, Daniel AriAmbuMeeting Participant or LecturerYes04/26/2022
Barocas, Daniel ArilantheusMeeting Participant or LecturerYes11/30/2022
Barocas, Daniel AriPacific Edge DiagnosticsMeeting Participant or LecturerYes12/01/2022
Barocas, Daniel AriOptum HealthConsultant or AdvisorYesCurrent
Carlsson, Sigrid ViktoriaNational Institutes of Health/National Cancer InstOther-Research FundingYesCurrent
Carlsson, Sigrid ViktoriaPrevent Cancer FoundationConsultant or AdvisorNoCurrent
Carlsson, Sigrid ViktoriaStudentlitteratur ABHealth PublishingYesCurrent
Carlsson, Sigrid ViktoriaNational Comprehensive Cancer Network (NCCN)Other-National Comprehensive Cancer Network Prostate Cancer Early Detection Guideline panel memberNoCurrent
Carlsson, Sigrid ViktoriaBritish Journal of Urology International (BJUI)Health PublishingYesCurrent
Carlsson, Sigrid ViktoriaJournal of Sexual Medicine (JSM)Health PublishingYesCurrent
Carlsson, Sigrid ViktoriaPatient Centered Outcomes Research Institute PCORIOther-Research FundingYes08/31/2021
Carlsson, Sigrid ViktoriaAUAConsultant or AdvisorNoCurrent
Carlsson, Sigrid ViktoriaWeill Cornell MedicineMeeting Participant or LecturerYes08/18/2021
Carlsson, Sigrid ViktoriaThe Chinese University of Hong KongMeeting Participant or LecturerYes10/30/2021
Carlsson, Sigrid ViktoriaMediahuset Gothenburg SwedenMeeting Participant or LecturerYes09/17/2021
Coakley, FergusOmnEcoil Instruments, Inc.OwnerYesCurrent
Eggener, Scott E.Profound MedicalConsultant or AdvisorYesCurrent
Eggener, Scott E.janssenMeeting Participant or LecturerYesCurrent
Eggener, Scott E.InsightecConsultant or AdvisorYesCurrent
Eggener, Scott E.ASCOHealth PublishingNoCurrent
Eggener, Scott E.Francis MedicalMeeting Participant or LecturerYesCurrent
Eggener, Scott E.CandelScientific Study or TrialNoCurrent
Eggener, Scott E.CellVaxConsultant or AdvisorYesCurrent
Eggener, Scott E.MetasTxConsultant or AdvisorYesCurrent
Etzioni, RuthNothing to disclose
Fine, Samson WilliamNothing to disclose
Han, MisopEigenOther-Patent licensedYesCurrent
Han, MisopNIHScientific Study or TrialNo02/19/2026
Kim, SennettNothing to disclose
Konety, Badrinath R.FKD TherapeuticsScientific Study or TrialYes06/30/2021
Konety, Badrinath R.Bristol Myers SquibbScientific Study or TrialNoCurrent
Konety, Badrinath R.Boston Scientific CorpConsultant or AdvisorYes12/31/2021
Konety, Badrinath R.Merck IncScientific Study or TrialYes06/03/2021
Konety, Badrinath R.Francis MedicalConsultant or AdvisorYes05/03/2021
Konety, Badrinath R.Convergent genomicsConsultant or AdvisorYesCurrent
Konety, Badrinath R.FerGene IncConsultant or AdvisorYes11/30/2020
Konety, Badrinath R.Nucleix IncConsultant or AdvisorYes11/30/2020
Konety, Badrinath R.PhotocureConsultant or AdvisorYesCurrent
Konety, Badrinath R.Astrin BiosciencesConsultant or AdvisorYesCurrent
Konety, Badrinath R.Styx BiotechnologyInvestment InterestYesCurrent
Lin, Daniel WeiNIH/NCIScientific Study or TrialYesCurrent
Lin, Daniel WeiDepartment of DefenseScientific Study or TrialYesCurrent
Lin, Daniel WeiGenomic Health, Inc.Scientific Study or TrialYes12/31/2020
Lin, Daniel WeiGenomeDxScientific Study or TrialNo12/31/2020
Lin, Daniel WeiAstellasConsultant or AdvisorNoCurrent
Lin, Daniel WeiMDxHealthScientific Study or TrialNoCurrent
Lin, Daniel WeiClovis OncologyConsultant or AdvisorYesCurrent
Lin, Daniel WeiMagForce USAScientific Study or TrialYesCurrent
Miner, Martin M.AntaresConsultant or AdvisorNo06/01/2021
Miner, Martin M.ClarusConsultant or AdvisorYes08/30/2022
Miner, Martin M.LipocineHealth PublishingNo01/01/2022
Miner, Martin M.AcerusConsultant or AdvisorYesCurrent
Miner, Martin M.HalozymeConsultant or AdvisorYesCurrent
Moses, Kelvin A.AstellasConsultant or AdvisorYes07/01/2021
Moses, Kelvin A.DendreonScientific Study or TrialYes01/01/2021
Moses, Kelvin A.PfizerConsultant or AdvisorYes07/01/2021
Moses, Kelvin A.PfizerScientific Study or TrialNo01/01/2021
Moses, Kelvin A.JanssenScientific Study or TrialNo01/01/2021
Nissenberg, Merel G.Nothing to disclose
Pinto, Peter AnthonyPhilips/InVivo IncOtherYesCurrent
Salami, Simpa SamuelNothing to disclose
Souter, LesleyNothing to disclose
Thompson Jr., Ian MurchieSWOGLeadership PositionNoCurrent
Thompson Jr., Ian MurchieMagForceConsultant or AdvisorYesCurrent
Thompson Jr., Ian MurchieThresholdConsultant or AdvisorYes06/25/2022
Thompson Jr., Ian MurchieHarvard UniversityConsultant or AdvisorYesCurrent
Thompson Jr., Ian MurchieH-E-B (grocery store chain)Leadership PositionYesCurrent
Thompson Jr., Ian MurchieNIH/NCI U01 GrantScientific Study or TrialYesCurrent
Wei, John ThomasNCIOtherNoCurrent
Wei, John ThomasSanofiConsultant or AdvisorYes08/15/2021

AUA Staff have nothing to disclose. 

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 11.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 11.00 AMA PRA Category 1 Credit™
  • 11.00 Non-Physician Participation
Please login or register to take this course.

Registration for this activity is limited to Early Detection of Prostate Cancer Guideline Panel Members only.